Trial Profile

Phase II study for the evaluation of neoadjuvant treatment with cabozantinib prior to cytoreductive nephrectomy in patients with locally advanced or metastatic renal cell carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms CABOPRE

Most Recent Events

27 Jan 2024 Results assessing change expression differences of selective mi-RNAs in plasma and TME previous before and after 12 first weeks of perioperatory cabozantinib,presented at the 2024 Genitourinary Cancers Symposium
02 Jul 2018 New trial record
05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com